Three-year follow-up after transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia using the PRIMUS U + R device

Scand J Urol Nephrol. 1999 Aug;33(4):217-21. doi: 10.1080/003655999750015808.

Abstract

Objective: We report long-term (3 years) follow-up data of transurethral microwave thermotherapy (TUMT) for benign prostatic hyperplasia (BPH) using a lower-power treatment protocol.

Material and methods: Ninety-one patients were treated in a 1-h session with the PRIMUS U + R device.

Results: Forty-five of the patients were still on TUMT monotherapy at 3-year follow-up, while 32 received additional therapy for their lower urinary tract symptoms. In patients with monotherapy there was a 45% decrease in international prostate symptom score (IPSS) when compared to pretreatment values. The moderate increase in peak uroflow seen early after TUMT could not be observed after 3 years. No serious side-effects were seen.

Conclusion: Three years after lower-power TUMT, 49% of patients treated were on TUMT monotherapy, while 35% received additional therapy for their voiding symptoms. Symptom score decreased 45% in patients with TUMT monotherapy concomitant with unchanged uroflow.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Evaluation Studies as Topic
  • Follow-Up Studies
  • Humans
  • Hyperthermia, Induced* / adverse effects
  • Hyperthermia, Induced* / instrumentation
  • Male
  • Microwaves*
  • Middle Aged
  • Patient Satisfaction
  • Prostatic Hyperplasia / physiopathology
  • Prostatic Hyperplasia / therapy*
  • Severity of Illness Index
  • Time
  • Time Factors
  • Urination / physiology